Novel homobarringtonie-containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy.

about

Novel homobarringtonie-containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy.

Item

http://www.wikidata.org/entity/Q49405566

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Novel homobarringtonie-contain ...... stant to conventional therapy.

@en

Novel homobarringtonie-contain ...... stant to conventional therapy.

@nl

type

Item

label

Novel homobarringtonie-contain ...... stant to conventional therapy.

@en

Novel homobarringtonie-contain ...... stant to conventional therapy.

@nl

prefLabel

Novel homobarringtonie-contain ...... stant to conventional therapy.

@en

Novel homobarringtonie-contain ...... stant to conventional therapy.

@nl

P1476

Novel homobarringtonie-contain ...... stant to conventional therapy.

@en

P2093

Jingjing Zhu

http://www.w3.org/2001/XMLSchema#string

Jingsong He

http://www.w3.org/2001/XMLSchema#string

Li Li

http://www.w3.org/2001/XMLSchema#string

Weiyan Zheng

http://www.w3.org/2001/XMLSchema#string

Wenjun Wu

http://www.w3.org/2001/XMLSchema#string

Xiujin Ye

http://www.w3.org/2001/XMLSchema#string

Yanlong Zheng

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group

Inhibition of translation in eukaryotic systems by harringtonine

Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

P304

7597-7607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.7084

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29344207

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

5755134

http://www.w3.org/2001/XMLSchema#string